Role of SWI/SNF chromatin remodeling genes in lung cancer development
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
SWI/SNF family of chromatin remodeling complexes uses the energy of ATP to change the structure of DNA, playing key roles in DNA regulation and repair. It is estimated that up to 25% of all human cancers contain alterations in SWI/SNF, although the precise molecular mechanisms for their involvement in tumor progression are largely unknown. Despite the improvements achieved in the last decades on our knowledge of lung cancer molecular biology, it remains the major cause of cancer-related deaths worldwide and it is in urgent need for new therapeutic alternatives. We and others have described recurrent alterations in different SWI/SNF genes in nearly 20% of lung cancer patients, some of them with a significant association with worse prognosis, indicating an important role of SWI/SNF in this fatal disease. These alterations might be therapeutically exploited, as it has been shown in cellular and animal models with the use of EGFR inhibitors, DNA-damaging agents and several immunotherapy approaches. Therefore, a better knowledge of the molecular mechanisms regulated by SWI/SNF alterations in lung cancer might be translated into a therapeutic improvement of this frequently lethal disease. In this review, we summarize all the evidence of SWI/SNF alterations in lung cancer, the current knowledge about the potential mechanisms involved in their tumorigenic role, as well as the results that support a potential exploitation of these alterations to improve the treatment of lung cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, up to 25% of all human cancers contain alterations in SWI/SNF, 54 although the precise molecular mechanisms of these pro-aging and pro-carcinogenic effects remain elusive.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [54]
In the citing paper
“Chromatin remodeling factors, such as heterochromatin protein 1a (HP1a), the SWI/SNF family, and the polycomb proteins, counteract both aging and cancer.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [54]
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,556
Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,458
SWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Self-citationExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
Self-citationA major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Kadoch, C., & Crabtree, G. R. (2015) · Science Advances · doi:10.1126/sciadv.1500447 · Cited by 828
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 789
Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
Mashtalir, N., D’Avino, A. R., Michel, B. C., Luo, J., Pan, J., Otto, J. E., Zullow, H. J., McKenzie, Z. M., Kubiak, R. L., St. Pierre, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.032 · Cited by 731
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 690
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522
Reisman, D., Sciarrotta, J., Wang, W., Funkhouser, W. K., & Weissman, B. E. (2003) · PubMed · Cited by 441
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma
Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D., Kannangai, R., Offerhaus, G. J. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.903 · Cited by 427
Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3480 · Cited by 418
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 387
SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation
Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Mieczkowski, J., Drier, Y., Gillespie, S. M., Archer, T. C., Wu, J. N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3746 · Cited by 370
Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 294
Nakayama, R. T., Pulice, J. L., Valencia, A. M., McBride, M. J., McKenzie, Z. M., Gillespie, M. A., Ku, W. L., Teng, M., Cui, K., Williams, R. T., et al. (2017) · Nature Genetics · doi:10.1038/ng.3958 · Cited by 291
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
Lee, H., Park, J., Kim, S., Kwon, S., & Kwon, J. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.27 · Cited by 264
Papillon, J. P. N., Nakajima, K., Adair, C. D., Hempel, J., Jouk, A. O., Karki, R. G., Mathieu, S., Möbitz, H., Ntaganda, R., Smith, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01318 · Cited by 244
Karnezis, A. N., Wang, Y., Ramos, P., Hendricks, W. P., Oliva, E., D'Angelo, E., Prat, J., Nucci, M. R., Nielsen, T. O., Chow, C., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4633 · Cited by 217
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers
Kelso, T. W. R., Porter, D. K., Amaral, M. L., Shokhirev, M. N., Benner, C., & Hargreaves, D. C. (2017) · eLife · doi:10.7554/elife.30506 · Cited by 192
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Xue, Y., Meehan, B., Fu, Z., Wang, X. Q. D., Fiset, P. O., Rieker, R., Levins, C., Kong, T., Zhu, X., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08380-1 · Cited by 187
Herpel, E., Rieker, R. J., Dienemann, H., Muley, T., Meister, M., Hartmann, A., Warth, A., & Agaimy, A. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2016.10.006 · Cited by 176
Burrows, A. E., Smogorzewska, A., & Elledge, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009559107 · Cited by 172
Romero, O. A., Torres-Diz, M., Pros, E., Savola, S., Gomez, A., Moran, S., Saez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 165
Schick, S., Rendeiro, A. F., Runggatscher, K., Ringler, A., Boidol, B., Hinkel, M., Májek, P., Vulliard, L., Penz, T., Parapatics, K., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0477-9 · Cited by 157
Bell, E. H., Chakraborty, A. R., Mo, X. M., Liu, Z., Shilo, K., Kirste, S., Stegmaier, P., McNulty, M., Karachaliou, N., Rosell, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1468 · Cited by 156
Matsubara, D., Kishaba, Y., Ishikawa, S., Sakatani, T., Oguni, S., Tamura, T., Hoshino, H., Sugiyama, Y., Endo, S., Murakami, Y., et al. (2013) · Cancer Science · doi:10.1111/cas.12065 · Cited by 131
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
Gonzalez-Perez, A., Jene-Sanz, A., & Lopez-Bigas, N. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 125
Romero, O. A., Setién, F., John, S., Giménez‐Xavier, P., Goméz-López, G., Pisano, D. G., Condom, E., Villanueva, A., Hager, G. L., & Sánchez‐Céspedes, M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200236 · Cited by 98
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency
Gupta, M., Concepcion, C. P., Fahey, C. G., Keshishian, H., Bhutkar, A. J., Brainson, C. F., Rivera, F. J. S., Pessina, P., Kim, J. Y., Simoneau, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1744 · Cited by 80
Lü, B., & Shi, H. (2019) · Journal of Cancer · doi:10.7150/jca.26978 · Cited by 76
Ray, A., Mir, S. N., Wani, G., Zhao, Q., Battu, A., Zhu, Q., Wang, Q.-E., & Wani, A. A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00503-09 · Cited by 71
Zhu, G., Shi, R., Li, Y., Zhang, Z., Xu, S., Chen, C., Cao, P., Zhang, H., Liu, M., Pan, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670040 · Cited by 69
Lovly, C. M., & Carbone, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.224 · Cited by 54
ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis
Zhang, Y., Xu, X., Zhang, M., Bai, X., Li, H., Kan, L., Niu, H., & He, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1755-x · Cited by 52
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors
Kahali, B., Yu, J., Marquez, S. B., Thompson, K. W., Liang, S. Y., Lü, L., & Reisman, D. (2014) · Oncotarget · doi:10.18632/oncotarget.1945 · Cited by 50
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
Papadakis, A. I., Sun, C., Knijnenburg, T., Xue, Y., Grernrum, W., Hölzel, M., Nijkamp, W., Wessels, L. F. A., Beijersbergen, R. L., Bernards, R., et al. (2015) · Cell Research · doi:10.1038/cr.2015.16 · Cited by 46
Moreno-Rodriguez, T., Monterde, B., González-Silva, L., Betancor-Fernández, I., Revilla, C., Agraz-Doblás, A., Freire, J., Marrón, P. I., Quevedo, L., Blanco, R. E., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01748-y · Cited by 46
Self-citationARID1A Gene Driver Mutations in Lung Adenocarcinomas
Karachaliou, N., Bracht, J. W. P., & Rosell, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.099 · Cited by 31
Harnessing mutual exclusivity between TP53 and ARID1 A mutations
Wu, S., Fatkhutdinov, N., & Zhang, R. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1377503 · Cited by 11
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Novel insights into regulators and functional modulators of adipogenesis
Kim, H., Jang, H., Muthamil, S., Shin, U. C., Lyu, J., Kim, S.-W., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117073 · Cited by 68
Wang, J., Shao, F., Yu, Q., Ye, L., Wusiman, D., Wu, R., Tuo, Z., Wang, Z., Li, D., Cho, W. C. S., et al. (2025) · Research · doi:10.34133/research.0612 · Cited by 72
“For example, alterations in the SWI/SNF complex are found in up to 25% of human cancer cases [ 179 ].”
ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications
Jin, F., Yang, Z., Shao, J., Tao, J., Reißfelder, C., Loges, S., Zhu, L., & Schölch, S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.005 · Cited by 44
SETD2-H3K36ME3: an important bridge between the environment and tumors
He, J., Xu, T., Zhao, F., Guo, J., & Hu, Q. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1204463 · Cited by 25
“described recurrent alterations of different SWI/SNF genes in nearly 20% of lung cancer patients, which were significantly associated with poorer prognosis, suggesting that SWI/SNF genes plays an important role in lung cancer (Monterde and Varela, 2022).”
Background
Metadata
- Authors
- Monterde, B., & Varela, I.
- Affiliations
- Universidad de Cantabria (ES)
- Corresponding author
- Varela, Ignacio
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2022-05-19
- Volume
- 50
- Issue
- 3
- Pages
- 1143-1150
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W4280641528
- Cited by
- 13
- References
- 52
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 2 · 2023: 6
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- SWI/SNF complex, chromatin remodeling, lung cancer, tumor progression, prognostic factors, EGFR inhibitors, DNA-damaging agents, immunotherapy, cancer therapy, chromatin structure
- MeSH terms
- Animals, Chromatin, Immunotherapy, Lung Neoplasms, Transcription Factors, Chromatin Assembly and Disassembly, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.